Neuropeptide Research Lab

Research Focus



Probe Development

Drug Discovery

Drug Development

Therapeutic Focus


Gastrointestinal disorders such as inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), or chronic abdominal pain affect 10-15% of the western population and have a substantial socio-economic impact on our society. The aetiology of these disorders are still unclear and therapeutic treatments focus mostly on symptoms rather than on the underlying causes.


We are exploring novel therapeutic strategies targeting gastrointestinal wound healing, protection and biofilms to reduce and prevent gastrointestinal disorders. 

A/Professor Markus Muttenthaler is a medicinal chemist working at the interface of chemistry and biology with a strong passion for translational research. His interests lie in neuropeptides and the exploration of nature's diversity (particularly venom peptides) to develop molecular tools, diagnostics and therapeutics. His background in drug discovery and development and his interdisciplinary training in chemistry and pharmacology assist him in the characterisation of these highly potent and selective compounds and allow him to study their interactions with human physiology for medical innovations in neuropathic pain, breast cancer, autism, gastrointestinal disorders and neurodegenerative diseases.